Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: SESOTHO trial (“Switch Either near Suppression Or THOusand”) – switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa

Fig. 1

Flow Chart of the SESOTHO trial: screening, randomization and primary endpoint. The first part of the flow chart (incl. EAC and follow-up VL) represents routine ART monitoring in the study district. a 10–14 weeks after the time point the patient has been informed. b stratified by centres, demographic groups and VL level at enrolment

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us